Market Overview

UPDATE: JMP Securities Reiterates Coverage on ARIAD Pharmaceuticals, Sees Market Share Regain

Share:
Related ARIA
These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
ARIAD Offers Updated Clinical Data for Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer

In a report published Monday, JMP Securities analyst Michael King reiterated Market Outperform on ARAID Pharmaceuticals, Inc. (NASDAQ: ARIA), with a $10.00 price target.

According to the report, ARIA is gearing up to recapture market share in both the T315I and later-line CML market with a restored, slimmed-down version of its sales force specifically targeting high prescription writers.

“FY14 should continue to be a catalyst-filled year with several data updates planned for ASCO (including GIST data) and EHA, along with the start of the randomized multi-dose study that should commence by 2H14,” the report noted. “Overall, management commentary on several fronts reinforces our positive outlook for 2014.”

ARIA closed Friday at $6.74.

Latest Ratings for ARIA

DateFirmActionFromTo
Dec 2014Credit SuisseDowngradesNeutralUnderperform
Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: JMP Securities Michael KingAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...